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Purpose: Diagnosis of genetic disorders is hampered by large
numbers of variants of uncertain significance (VUSs) identified
through next-generation sequencing. Many such variants may
disrupt normal RNA splicing. We examined effects on splicing of a
large cohort of clinically identified variants and compared
performance of bioinformatic splicing prediction tools commonly
used in diagnostic laboratories.
Methods: Two hundred fifty-seven variants (coding and noncod-
ing) were referred for analysis across three laboratories. Blood RNA
samples underwent targeted reverse transcription polymerase chain
reaction (RT-PCR) analysis with Sanger sequencing of PCR
products and agarose gel electrophoresis. Seventeen samples also
underwent transcriptome-wide RNA sequencing with targeted
splicing analysis based on Sashimi plot visualization. Bioinformatic
splicing predictions were obtained using Alamut, HSF 3.1, and
SpliceAI software.
Results: Eighty-five variants (33%) were associated with abnormal
splicing. The most frequent abnormality was upstream exon
skipping (39/85 variants), which was most often associated with
splice donor region variants. SpliceAI had greatest accuracy in
predicting splicing abnormalities (0.91) and outperformed other
tools in sensitivity and specificity.
Conclusion: Splicing analysis of blood RNA identifies diagnosti-
cally important splicing abnormalities and clarifies functional
effects of a significant proportion of VUSs. Bioinformatic predic-
tions are improving but still make significant errors. RNA analysis
should therefore be routinely considered in genetic disease
diagnostics.
Genetics inMedicine (2020) 22:1005–1014; https://doi.org/10.1038/s41436-
020-0766-9
Keywords: RNA splicing; variant interpretation; genetic diag-
nosis; genomic medicine; RNA-seq
INTRODUCTION
Use of next-generation sequencing (NGS) technologies in
clinical practice has led to an unprecedented increase in the
number of variants being identified in patients undergoing
investigation for genetic disorders. Incomplete knowledge of
the functional effects of variants and our limited understanding
of genotype–phenotype correlations severely compromises
attempts to definitively assign or refute pathogenicity for a
large proportion of variants. Variant of uncertain significance
(VUS) reporting rates vary over time and depending on local
reporting policies but of all variants listed on ClinVar (as of 13
November 2019), 48% are asserted to be of uncertain
significance (Figure S1).1 In a clinical setting, this uncertainty
has major implications for patients and their families, where
having a clear genetic diagnosis can allow evidence-based
management decisions to be taken and informed reproductive
choices to be made.2,3
RNA splicing is thought to be disrupted by up to 62% of
all pathogenic single-nucleotide variants (SNVs).4 Current
bioinformatic filtering strategies and clinical interpretation
guidelines tend to focus heavily on amino acid–level effects in
terms of both variant detection and assignment of pathogeni-
city.5 This can lead to synonymous variants being filtered out at
an early stage of analysis, even though such variants may affect
splicing. Similarly, although deep intronic variant data are
increasingly available via NGS approaches like genome sequen-
cing, such noncoding variants are rarely considered owing to a
lack of evidence on which to base interpretations. Where
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bioinformatic predictions suggest that a variant affects splicing,
there can be scope for additional RNA-based investigations.
However, such splicing prediction tools frequently produce
conflicting results and their accuracy and utility decreases
outside of canonical splice sites and consensus splice regions.6
In this study, we looked for RNA splicing defects in a large
cohort of VUSs identified in patients who had undergone
diagnostic genetic testing. We compare in silico predictions of
splicing with the results of blood RNA analysis and provide
examples that illustrate the clinical utility of RNA-based
testing in clinical diagnostics. These results support the
routine use of RNA analysis in clinical diagnostic practice.
MATERIALS AND METHODS
Patients and variants
A cohort of patients with VUSs identified through routine
diagnostic genetic testing was identified primarily through the
Wessex Regional Genetics Laboratory, Salisbury (203 variants),
with seven other patients identified through the Exeter Genomics
Laboratory. Additional patients with 47 variants from across the
UK were identified through the Splicing and Disease research
study at the University of Southampton, ethically approved by
the Health Research Authority (IRAS Project ID 49685, REC 11/
SC/0269) and by the University of Southampton (ERGO ID
23056). Informed consent for splicing studies was provided for
all patients from whom samples were obtained.
RNA extraction and cDNA preparation
Blood was collected in PAXgene Blood RNA tubes and RNA
extracted using the PAXgene Blood RNA Kit (PreAnalytiX,
Switzerland). Complementary DNA (cDNA) was synthesized
via reverse transcription using random hexamer primers. For
details of each laboratory’s individual protocols, see Supple-
mentary Methods.
Reverse transcription polymerase chain reaction (RT-PCR)
analysis
Primers were designed to amplify the region around each
variant (sequences available on request). Wherever possible,
primer sequences were positioned at least two exons up- and
downstream of the target variant. PCR products were evaluated
by agarose gel electrophoresis against control samples and
purified PCR products were analyzed by direct Sanger
sequencing. In a number of cases, PCR products separated by
gel electrophoresis were purified and sequenced or cloned into
E. coli using a TA-cloning vector. Plasmids recovered from
single-clone bacterial cultures were analyzed by Sanger sequen-
cing. Please see Supplementary Methods for laboratory-specific
PCR, Sanger sequencing, and bacterial cloning conditions.
RNA-seq analysis
For full information, see Supplementary Methods. In brief,
selected RNA samples underwent RNA-seq via Novogene
(Hong Kong) using the NEBNext Globin and rRNA Depletion
Kit and NEBNext Ultra Directional RNA Library Prep Kit for
Illumina (New England Biolabs, MA). At least 70M 150-bp
paired-end reads (21 Gb raw data) per sample were generated
on a HiSeq 2000 instrument (Illumina, CA). Raw data were
filtered for quality and had adapter sequences removed by
Novogene. Reads were aligned to the human genome (GRCh38)
using STAR (v2.6.1c)7 on the University of Southampton’s
IRIDIS 4 high performance computing cluster and the splicing
effects of specific variants was assessed visually using the
Integrative Genomics Viewer8 (Broad Institute, MA) and its
inbuilt Sashimi plot function.9 A threshold of three or more
reads was required to call an abnormal splice event and use of
the novel junction had to reach at least 5% read support
compared with the alternative canonical junction. Where
appropriate, percent spliced in (PSI) values were calculated for
abnormal splicing events.10
In silico splicing predictions
All variants were assessed bioinformatically for predicted
splicing effects using Alamut Visual version 2.11 (Interactive
Biosoftware, Rouen, France), which incorporates predictions
from MaxEntScan (MES), NNSplice, and Splice Site Finder
(SSF).11–13 Individual tools were deemed to predict altered
splicing where the change in splice site score was ≥10% (MES)
or ≥5% (NNSplice and SSF).14,15 An overall prediction of altered
splicing was called where two of three Alamut programs agreed.
Additional splice prediction information was obtained using
Human Splicing Finder (HSF) version 3.1 (threshold≥ 0.2) and
from publicly available SpliceAI scores (v1.3) for variants
(threshold ≥ 0.2).16,17 Missing score rate, sensitivity, specificity,
overall accuracy, and positive and negative predictive values
were calculated for each tool individually and for the combined
Alamut 2/3 assessment (equations in Supplementary Methods).
The package pROC (v1.15.3)18 was used in R (v3.5.1)19 in
RStudio20 to plot receiver operating characteristic (ROC) curves
(ggplot2, v3.2.1)21 for the overlapping set of variants scored by
all tools and calculate the area under the curve (AUC) for each
tool and for the combined Alamut 2/3 assessment.
RESULTS
Variants affecting splicing
A total of 257 different variants were assessed for their effect
on splicing (Table S1). Two-hundred forty-three variants
were single-nucleotide substitutions, while 14 variants
spanned multiple nucleotides (10 deletions, 1 insertion, 2
deletion–insertions, and 1 deletion with an in cis SNV).
Variants were located across 62 genes in total, with
particularly high numbers of variants in BRCA1 (42),
BRCA2 (42), and FBN1 (87). In all, 85 variants (33%) were
found to be associated with abnormal splicing. Of 57 single-
nucleotide substitution variants, 44 (77%) located within the
donor splice site or splice region (defined by sequence
ontology as extending from the third last base of the exon up
to the eighth base of the intron) and 13/19 single-nucleotide
substitution variants (68%) located within the acceptor splice
site or splice region (from the eighth last base of the intron
up to the third base of the exon) were found to alter splicing
(Fig. 1).22 One hundred seventy-five variants in total did not
ARTICLE WAI et al
1
2
3
4
5
6
7
8
9
0
()
:,
;
1006 Volume 22 | Number 6 | June 2020 | GENETICS in MEDICINE
involve annotated splice regions and of these, 23 (13%)
affected splicing (21/167 single-nucleotide substitutions).
Thirty-nine variants were associated with skipping of the
upstream exon (as defined by the location of a variant lying
closer to that exon’s donor splice site than to an acceptor
splice site), which was the most frequent splicing abnormality
identified. Only 15 variants were associated with down-
stream exon skipping; however, the analyzed variant cohort
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contained relatively fewer acceptor region variants. These
exon skipping figures include three cases in which both
upstream and downstream exons were skipped and one case
of double upstream exon skipping. Twenty-three variants led
to use of an alternative splice donor site and 16 to use of an
alternative splice acceptor site, while intron retention was
associated with only three variants. For four variants there
were multiple splicing abnormalities identified.
Illustrative examples
Several examples from this cohort are pertinent in illustrating
the variability in splicing effect seen across different variants
(see Fig. 2).
RNA-seq detects a splice variant missed by Sanger
sequencing
This hemizygous DKC1 c.915+10G>A variant, identified in a
male patient with dyskeratosis congenita, produced normal
results from direct Sanger sequencing of RT-PCR products
(Fig. 2). Similarly, gel electrophoresis did not suggest the
presence of more than one RT-PCR product. However, RNA-
seq revealed creation of a novel intronic donor splice site,
resulting in an insertion of 11 extra nucleotides, which was
subsequently confirmed by isoform-specific RT-PCR and
sequencing of cloned amplicons. The novel junction had a PSI
value of 20%, calculated as the number of length-normalized
inclusion reads divided by the total number of length-
normalized inclusion and exclusion reads.10
A complex deep intronic variant affects splicing
This heterozygous P3H1 (LEPRE1) c.1224-80G>A variant was
identified in a patient with osteogenesis imperfecta. RT-PCR
revealed a variety of differently sized bands on electrophoresis
and PCR product cloning identified at least four alternative
splicing events, including intron retention, creation of two
novel intronic splice donor sites (inserting 68 or 92 nt), with
some additional use of an alternative exonic splice acceptor
site (inserting 92 nt intronic sequence but deleting the first 17
nt of exon 8). RNA-seq analysis was only able to confidently
identify use of one of the two intronic splice donor sites.
Interestingly, the amino acid sequence of any intron retention
event (including those utilizing the subsequent novel intronic
donor site) is predicted to result in introduction of a
premature termination codon immediately beyond the end
of exon 7.
An apparent canonical splice site variant has no
consequence
A heterozygous canonical splice donor site DCTN1 c.414+
1G>A variant in intron 5 was predicted to disrupt splicing
based on NM_004082.4. However, the variant was found to be
present at a relatively high minor allele frequency (MAF) of
3.0 × 10−4 in the Latino population and 6.4 × 10−5 in the
gnomAD database (rs576198476). RT-PCR analysis identified
that DCTN1 exons 5–7 are in fact constitutively skipped in
both this patient and in controls, negating any potential
splicing effects caused by the variant.
A deep exonic cryptic splice site
This heterozygous BRCA1 c.4868C>G transversion 119 nt
upstream from the donor splice site of BRCA1 exon 15 is
predicted to introduce a conservative alanine to glycine
substitution at amino acid 1623. However, RNA analysis
shows that this variant in fact creates an exonic cryptic splice
donor site at this position, leading to a 119-nt deletion and
frameshift of the transcript.
A “likely benign” intronic variant causes pathogenic exon
skipping
A heterozygous noncoding BRCA1 c.5153-26A>G transition
26 nt upstream from the start of exon 18 is annotated as
“likely benign” on ClinVar (rs80358109). However, RNA
analysis confirms that this variant induces skipping of the
downstream exon 18, resulting in an out-of-frame transcript.
Interestingly, although there is no predicted effect on the
native splice acceptor site, several prediction tools incorrectly
suggest creation of a novel cryptic acceptor site.
A deep intraexonic splice effect
A heterozygous SF3B4 c.417C>T synonymous variant located
254 nt into exon 3 was predicted to lead to an enhanced
alternative splice site. RT-PCR analysis confirmed the creation
of an alternative deep exonic splice donor site. However, use of
this novel donor site was found to be coupled to use of a novel
splice acceptor site also within SF3B4 exon 3, leading to an
intraexonic deletion of 125 nt. This effect has previously been
reported for this variant using a minigene assay.23
RNA-seq coverage
Seventeen samples also underwent RNA-seq analysis. In four
cases, RNA-seq was able to detect a splicing abnormality
Fig. 1 Variant locations and effects on splicing. (a) Plot of the numbers of single-nucleotide variants (SNVs) in this cohort (multinucleotide variants not
included) present at each donor (D-3 to D+8) and acceptor (A-8 to A+3) splice region position, along with the numbers of these found to affect splicing.
(b, c) Position–weight matrices of nucleotide sequence across the splice donor (b) and acceptor (c) regions as determined for the specific exon–intron
junctions analyzed in this study. In this representation, the donor splice site +1 position correlates to position 12 in (b), while the acceptor splice site
−1 position correlates to position 25 in (c). (d) Abnormal splicing effects plotted by SNV location. Sequence ontology defines the donor splice region as
extending from the third last nucleotide of the exon (D-3) to the eighth nucleotide of the intron (D+8) and the acceptor splice region as extending form the
eighth last nucleotide of the intron (A-8) to the third nucleotide of the exon (A+3).22 (e) Overall proportion of all variants affecting splicing in this cohort.
(f) Proportions of different abnormal splicing events identified in this cohort. A3SS alternative 3´ splice site; A5SS alternative 5´ splice site, IR intron retention,
SE skipped exon.
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consistent with initial RT-PCR results. In one case (DKC1),
RNA-seq identified a splicing abnormality not initially
detected by RT-PCR. In another case (SF3B4), the splicing
abnormality seen by RT-PCR was only seen in two RNA-seq
reads and so fell below the reporting threshold. In 11 other
cases, no reportable splicing abnormality was detected. Of
note, splice junction depth of coverage varied considerably
across assayed genes and also within genes, which in several
cases limited the ability of RNA-seq to detect low-level splice
junction usage.
Bioinformatic splicing predictions
We scored all variants with Alamut Visual (v2.11), including
MES, NNSplice, and SSF, and also with HSF and SpliceAI.
Thresholds for change were selected above which a variant
was deemed to be predicted to be splice affecting based on
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Fig. 2 Illustrative examples of variant splicing analysis. DKC1 c.915+10G>A could not be identified by reverse transcription polymerase chain
reaction (RT-PCR) and Sanger sequencing but alternative donor splice site usage was identified by RNA-seq. P3H1 (LEPRE1) c.1224-80G>A causes at least
three abnormal splicing events using alternative splice donor and acceptor sites, as well as increasing levels of intron retention. DCTN1 c.414+1G>A appears
to alter a canonical splice donor site but exons 5–7, although annotated, are never expressed and are constitutively spliced out. SF3B4 c.417C>T is a
synonymous coding variant but causes formation of a 125-nt “exitron,” an intronic region within an exon. A3SS alternative 3´splice site, A5SS alternative 5´
splice site, Ctrl control, Pt patient.
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previous literature.14,15,17 A combined Alamut score was also
calculated, where a variant was deemed to be predicted as
splice affecting if two of three individual tools within Alamut
passed the defined threshold. The overall sensitivity, specifi-
city, accuracy, and positive and negative predictive values for
each tool and the combined Alamut assessment are given in
Table 1, based on all variants that were scored by each
method. Figure 3 shows ROC curves with AUC values based
on the overlapping set of variants scored by all tools. SpliceAI
performed the best in predictions of splicing disruption of all
the tools/approaches across all of the considered metrics, with
overall accuracy exceeding 90% (see Table 1).
DISCUSSION
VUS clarification and clinical impact through
splicing analysis
This study has helped to clarify the effects on splicing of over
250 VUSs in clinically important disease genes. Thirty-four
percent of these VUSs were found to affect splicing. However,
while this overall figure is certainly within the range of
previous estimates for the proportion of variants affecting
splicing, it should be noted that this cohort of variants was
specifically selected for splicing studies. As such, there will
have been some intrinsic bias in selection, since we expect
variants were more likely to be referred for RNA studies if
they fell within a splice region or if clinical diagnostic
laboratories had already highlighted a potential predicted
effect on splicing. Furthermore, the prior probability of these
patients having a pathogenic variant in the genes tested is
likely to be increased, since UK diagnostic genetic testing
generally requires that a patient’s phenotype potentially fits
with the genes being tested. Nevertheless, this cohort does
represent a true-to-life set of clinically identified VUSs for
which clarification of pathogenicity was sought by referring
clinicians.
The results of this study show that RNA splicing analysis,
using RT-PCR or transcriptomics, has the ability to produce
clear results that help clarify variant interpretation. Where
abnormal splicing is detected, this analysis constitutes a
functional assay that provides supporting evidence of patho-
genicity.5 In many such cases, these results therefore have direct
clinical utility by allowing a genetic diagnosis to be made.
Indeed, the results of at least one of these cases (AARS)
has been used to inform prenatal testing in a subsequent
pregnancy.
Only 30% of the variants in this study fell within annotated
splice regions, while 13% of non–splice region variants still
affected splicing. This highlights the need to consider possible
splicing effects whenever deep exonic or deep intronic variants
are identified. With increasing use of genome sequencing,
increasing numbers of intronic variants will be identified
through clinical diagnostic testing. Interpretation of such
variants beyond the splice region remains largely uncertain.
Table 1 Performance assessment of in silico prediction tools on experimentally validated variants (n= 257).
Scoring metric n Missing Sensitivity Specificity Accuracy PPV NPV
HSF (2%) 28 0.8941 0.3958 0.5808 0.4663 0.8636
SpliceAI (0.2) 11 0.8987 0.9162 0.9106 0.8353 0.9503
Alamut SSF (5%) 5 0.7317 0.9294 0.8651 0.8333 0.8778
Alamut MES (10%) 1 0.7381 0.9070 0.8516 0.7949 0.8764
Alamut NNSplice (5%) 11 0.6923 0.8631 0.8089 0.7013 0.8580
Alamut 2/3 14a 0.7237 0.9162 0.8560 0.7971 0.8793
Values have been calculated omitting the missing scores for each tool.
HSF Human Splicing Finder, MES MaxEntScan, NPV negative predictive value, PPV positive predictive value, SSF Splice Site Finder.
a11 variants missing one score, three variants missing two scores.
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However, through RNA analysis, potential splicing effects of
such variants can be detected.
Furthermore, a number of these results illustrate the danger
of assuming the effects of splice site variants. The DCTN1
c.414+1G>A example is a case in point of a benign canonical
splice site variant and our cohort also includes two normal
BRCA2 canonical splice site variants (BRCA2 c.6937+1G>T
and BRCA2 c.8331+2T>C) that do not appear to cause
abnormal splicing (with the caveat that splicing effects in
blood may potentially differ from those in other tissues). In
addition, the SF3B4 example shows how difficult it can be to
predict splice junction usage, since even if one correctly
identifies creation of a cryptic donor site, one may not
necessarily predict the acceptor site it will use. This particular
variant appears to create a type of noncanonical splicing event
known as an “exitron,” where a novel intron is defined
entirely within a large exon.24
Targeted testing and transcriptome-wide analysis
Our analysis helps provide some insight into the comparative
use of RT-PCR and RNA-seq to look at splicing. Compared
with transcriptome-wide RNA-seq, RT-PCR should generally
prove more sensitive for detecting substantial splicing
abnormalities such as exon skipping, since targeted amplifica-
tion allows a very low limit of detection. However, endpoint
RT-PCR and Sanger sequencing are not truly quantitative
methods and suffer from biases such as preferential amplifica-
tion of shorter products. Whole-transcriptome RNA-seq,
conversely, may provide more reliable quantification of splice
isoforms through calculated read-based metrics such as PSI
values.10 On the other hand, transcriptome-wide RNA-seq is
intrinsically limited in its depth of coverage by the number of
reads obtained per sample, particularly where a gene is poorly
expressed. A number of RNA-seq samples in this cohort did
indeed have relatively poor coverage across the target region
for the variants in question. However, where a splice
abnormality results in a small-scale change, for example
insertion of a few nucleotides as seen with DKC1 c.915+
10G>A, RNA-seq may succeed in identifying this where
Sanger sequencing of PCR products fails. Small-scale splicing
changes are easily missed on gel electrophoresis and coupled
with the poor sensitivity of Sanger sequencing to detect low-
level sample heterogeneity, this is an instance where RNA-seq
can outperform RT-PCR. Another potential approach to raise
coverage depth could be to perform a targeted RNA-seq
library prep focused on the gene region of interest. However,
this would be at the expense of RNA-seq’s other great
advantage: the ability to look for alternative pathogenic
splicing events or even alternative pathogenic sequence
variants in the same or in other genes.
Bioinformatic tool comparison
The ability to accurately predict the effect a given sequence
variant will have on splicing is highly desirable in prioritizing
variants for functional validation, or even as a diagnostic
assessment in its own right. However, despite a multitude of
different prediction methods being available, there is little
consensus on the best tools or the optimal usage and score
thresholds to use. A common approach is to score a variant
with several (three to five) tools and take a consensus
approach—if the majority of tools predict an effect, the
variant is predicted to be splice affecting. In our assessment,
we found little benefit of this consensus approach over the use
of individual tools. Across all scored variants the Alamut 2/3
consensus gave similar sensitivity and specificity to compo-
nent tools MES and SSF, and gave a comparable AUC in the
analysis considering the overlapping variant set that were
scored by all tools. The newer, machine learning–based
approach, SpliceAI, outperformed the other tools across
metrics, classifying over 90% of variants consistently with the
experimental data. Our data suggest this method could assist
in clinical interpretation of variants potentially affecting
splicing, and offer benefits over existing approaches that are
currently in use diagnostically.
Despite questions over the accuracy and applicability of in
silico splice prediction tools, in this cohort, a high proportion
of variants were correctly predicted to alter normal splicing,
particularly given the high proportion of variants outside of
the immediate splicing area.14,15 However, this is likely to be
at least partially explained by the bias in case selection, since
we expect variants were more likely to be referred for splicing
analysis where diagnostic genetic test reports had predicted a
possible splicing effect.
Limitations of testing and using blood as a proxy tissue
In analyzing blood RNA, there are intrinsic limitations. Most
obviously, only genes that are transcribed in blood can be
detected. Genes that are highly tissue-specific in their expression
can therefore prove problematic to analyze. Alternative cell
types may be available in some cases from skin or muscle
biopsies and RNA from such sources has been successfully used
for splicing analysis.25,26 However, even in the absence of such
samples, low-level basal transcription of the genome is known
to take place and some 80% of all human coding sequences have
been identified in blood.27 In this study, reference was made to
GTEx transcript per million (TPM) values (Table S1).28,29
Interestingly, informative RT-PCR results were obtainable for a
number of genes reported to have TPM values of zero (FBN2,
COL3A1, COL4A1, COL5A1), although this is not reliably the
case for all such genes.
A further important consideration is the tissue specificity of
splicing. Use of blood as a proxy tissue assumes that similar
splicing events are taking place in clinically relevant tissues,
which is not necessarily the case. Another limitation in
detection may occur if nonsense-mediated decay (NMD) is
efficient enough to remove all abnormally spliced transcripts
from a sample. Indeed, variability in NMD contributes to
uncertainty in quantifying the relative usage of aberrant splice
events.30,31 This means that simple quantification metrics of
splice site usage are unlikely to be directly informative of
pathogenicity and need to be considered in comparison with
control samples.
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Mechanistic insights into splicing
A notable finding in this study is that splice-altering variants
located close to the donor splice site tend to cause skipping of
the upstream exon. In considering the splicing reaction, where
the donor splice site is first cleaved and ligated to the intronic
branch point to form a lariat, one might expect a disrupted
donor splice site to cause intron retention. However, retention
of introns appears to be a relatively rare event in this study.
Furthermore, the presence of upstream exon skipping in these
cases implies that splicing of the preceding intron has not yet
been completed by the time the next intron is being spliced.
If upstream splicing were complete, there would be no
upstream donor splice site available to allow exon skipping to
take place (Fig. 4), except in the setting of a recursive splicing
mechanism.24
Splicing is known to occur cotranscriptionally and the
choice of splice site depends not only on sequence but also
on additional factors such as rate of transcription, RNA
secondary structure, chromatin conformation, and the effects
of splicing enhancers and silencers.32 It may be that some of
these factors are playing a role in driving the upstream exon
skipping that predominates in this variant cohort. The timing
of splicing events may also potentially be influenced some-
what by intron length. However, analysis of the intron–exon
structure around these variants did not indicate any
significant skewing of upstream versus downstream intron
length.
Further work will be needed to better characterize the
mechanistic and regulatory elements of the abnormal splicing
seen in this study. Understanding the underlying mechanisms
governing such splicing abnormalities is critical, not only to
allow their better prediction but also to inform therapeutic
approaches that aim to correct them. Splice-switching
antisense oligonucleotide (ASO) therapies are increasingly
being developed for clinical use and their design depends
upon accurate targeting of disease-specific splice sites or
splice-regulatory elements.33,34 The sequence specificity of
this approach lends itself ideally to personalized medicine and
indeed such a drug has recently been developed for an N-of-
1 study in a single patient with a deep intronic variant
affecting splicing.35 In the appropriate disease settings, splice-
affecting variants lying within deep intronic or exonic regions
therefore represent particularly good candidates for the
development of splice-switching ASO therapeutic approaches.
Conclusion
This variant cohort is among the largest and most diverse to
have had experimentally determined RNA splicing effects
analyzed and published to date. While routine use of RNA
analysis in genetic diagnostics requires further work to clarify
the service implications, based on this study, we recommend
that RNA-based splicing analysis be at least routinely
considered in genetic disease variant interpretation to improve
diagnostic uplift. While bioinformatic splicing prediction tools,
Donor
site variant
Donor
site variant
Acceptor
site variant
Acceptor
site variant
Preceding splice
event complete
Preceding splice
event incomplete
Exonic or intronic variant
Intronic or exonic variant
Exon Exon
Exon
Exon
Exon Exon
Exon
Exon
Exon
Exon
Exon
Exon
Intron
retention
Upstream
exon skipping
Downstream
exon skipping
Alternative splice
donor site
Alternative splice
acceptor site
Fig. 4 A potential model of splicing disruption. Where an upstream splicing event is complete, a splice donor or acceptor site variant may lead to intron
retention. Where a preceding splicing event remains incomplete, a splice donor variant may cause skipping of the upstream exon. Similarly, if a splice
acceptor site variant causes an upstream splice donor site to remain unused then this may cause skipping of the exon downstream of the acceptor site
variant. Exonic or intronic variants that create or strengthen cryptic splice sites can lead to use of alternative splice donor or acceptor sites.
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particularly SpliceAI, continue to improve in accuracy, there is
still significant miscalling of predictions from all tools. Ideally,
they should therefore not be relied upon in isolation in
assessing a variant’s effect on splicing and their predictions
should not be a prerequisite line of evidence for classifying
splice variants, should clear experimentally obtained RNA
splicing evidence be available. Owing to the subtlety and
complexity of RNA splicing, additional work will be required
to determine how best to incorporate splicing predictions and
experimental splicing analysis into variant classification
guidelines.
In conclusion, this large study demonstrates the potential of
blood RNA analysis in clarifying the effects of variants of
unknown significance and the uplift of diagnostic rate.
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